Prostaglandins are implicated in the labor process, yet the precise role and regulation of the prostaglandin pathway remains to be elucidated. The first step in the pathway is cleavage of membrane phospholipids by phospholipase A 2 (PLA 2 ). Previous work demonstrated upregulation of secretory PLA 2 (sPLA 2 )-IIA with labor in human myometrium, and recent evidence shows that there are numerous PLA 2 isoforms. The present study investigates the potential of additional sPLA 2 isoforms during pregnancy and labor. Real-time reverse transcriptase-polymerase chain reaction (RT-PCR), Western blotting, and immunohistochemistry were used to determine sPLA 2 expression and localization. Results show the presence of sPLA 2 -IID in amnion, chorion, placenta, decidua, and myometrium. Expression of sPLA 2 -IID in decidua was significantly decreased in term labor compared to nonlabor patients, whereas no significant labor-associated changes were observed in other gestational tissues. Secretory PLA 2 -IID was localized within chorion fibroblasts, placenta trophoblasts, decidual cells, and in myometrial smooth muscle cells. In primary decidual cell cultures, interleukin (IL) 10 (IL-10) increased sPLA 2 -IID messenger RNA (mRNA) expression, while IL-1b had no effect on sPLA 2 -IID mRNA expression. In conclusion, decreased expression of sPLA 2 -IID in the decidua at labor indicates that it is unlikely to contribute to increased prostaglandin production during labor. However, increased expression of sPLA 2 -IID, induced by IL-10, suggests that sPLA 2 -IID may play an important anti-inflammatory role at the maternal-fetal interface. Nevertheless, precise functions of sPLA 2 -IID within the human uterus remain to be determined.
Introduction
Strong evidence supports a pivotal role for prostaglandins (PGs) in uterine contractility and cervical ripening, key processes that characterize human labor, and prostaglandin production is known to be increased with labor onset. [1] [2] [3] [4] [5] [6] In clinical practice, prostaglandin analogs are used to induce labor, 7, 8 and inhibitors of prostaglandin synthesis to delay preterm labor 9 , yet the use of these compounds is not always optimal, [10] [11] [12] largely due to our incomplete understanding of the complex role that prostaglandins play in both maternal and fetal gestational tissues.
Prostaglandin synthesis involves 3 rate-limiting steps 13 (1) cleavage of arachidonic acid (AA) from membrane phospholipids mediated by phospholipase A 2 (PLA 2 ) enzymes; (2) conversion of free AA to intermediate prostaglandin molecules, PGG 2 and PGH 2 , by the action of cyclooxygenase enzymes, COX-1 and COX-2; and (3) conversion of the intermediate components into distinct prostaglandins by the action of specific PG synthase enzymes. Hence, the increased prostaglandin output observed with labor may be mediated by increased activity at any or each of the above-mentioned steps. However, it is not clear which step is critical for prostaglandin production nor has it been determined which PLA 2 enzymes are responsible for the increase in PG synthesis at the time of labor.
From the large PLA 2 ''superfamily,'' more than 20 distinct members have been identified in human tissues. 14 The PLA 2 isoforms that differ in molecular size, cellular localization, and substrate specificity are broadly classified into 5 categories: secretory phospholipases (sPLA 2 ), Ca 2þ -dependent cytosolic phospholipases (cPLA 2 ), Ca 2þ -independent phospholipases (iPLA 2 ), platelet-activating factor acetylhydrolase (PAF-AH), and lysosomal PLA 2 . 15, 16 These PLA 2 groups are further divided into subgroups. For example, the largest group, sPLA 2 , includes subgroups I, II, III, V, IX, X, XI, XII, XIII, and XIV. The physiological significance of why multiple PLA 2 isoforms exist is not fully understood. However, with the availability of different PLA 2 enzymes, the potential exists for increased variability or specificity of prostaglandin production within each tissue or cell type. The sPLA 2 group, for example, has been implicated in the generation of diverse kinds of phospholipid-derived mediators. 16 Several members of the sPLA 2 family have been shown to play a role in inflammatory, immune, and apoptotic processes and disease progression, 17, 18, 19 hence the interest in developing selective inhibitors for each of these subtypes. 20, 21 To our knowledge, only 3 of the known PLA 2 enzymes have been identified and partially characterized in the pregnant human uterus, including sPLA 2 -IIA, sPLA 2 -V, and cPLA 2 -IV. 22, 23 These isoforms are differentially expressed and regulated throughout pregnancy and parturition, [24] [25] [26] [27] [28] [29] suggesting different downstream cellular effects. However, these changes do not account for the overall increase in PLA 2 activity observed during pregnancy, suggesting the presence of other PLA 2 enzymes within the pregnant uterus. We performed an initial reverse transcriptase-polymerase chain reaction (RT-PCR) screen and identified the expression of a new secretory PLA 2 enzyme, sPLA 2 -group IID (sPLA 2 -IID) within the pregnant human uterus. 30 Secretory PLA 2 -IID was first described in the mouse 31 and more recently was identified in endothelial cells of the capillary vessels of rheumatoid arthritis patients 32 and within mast cells of the human lung 33 and appears to play a role in cytokine-mediated inflammation 19 and immunosuppression. 17 To date, however, there is no information available regarding the sPLA 2 -IID expression and regulation in human gestational tissues with labor.
Therefore, the aims of this study were to determine the expression pattern of sPLA 2 -IID within human gestational tissues (amnion, chorion, placenta, decidua, and myometrium) at term and to ascertain any labor-associated changes in sPLA 2 -IID expression in the gestational tissues. Following the identification of labor-associated changes in the decidua, the next aim of this study was to investigate the regulatory mechanisms of sPLA 2 -IID expression. For this aim, we used an in vitro explant model of cultured decidual cells to examine the effects of interleukin (IL) 1b (IL-1b) and IL-10 on sPLA 2 -IID expression.
Materials and Methods

Tissue Collection
Human gestational tissues were collected following ethics approval and informed consent (Office of Medical Bioethics, University of Calgary) from women with healthy pregnancies who were undergoing cesarean section (CS) at term. Indications for CS included breech presentation, previous CS, placenta previa, and fetal distress. Samples were collected from healthy term singleton pregnancies, before labor (term nonlabor, TNL; n ¼ 12) or after labor (term labor, TL; n ¼ 12). Clinical characteristics of labor in the patients included in the study are presented in Table 1 . After delivery of the baby, amnion, chorion, and placental samples were isolated. The amnion and chorion samples were obtained from below the incision site of the lower uterine segment at cesarean section delivery. The placental samples were obtained from the middle of the placental disk. In addition, myometrium and decidua biopsies were obtained from within the uterus at the upper margin of the lower uterine segment. Samples were either frozen and stored at À80 C prior to RNA and protein isolation or fixed in 10% neutral-buffered formalin prior to paraffin embedding for immunohistochemistry. Decidua biopsies were also obtained from an additional 4 patients for generating decidua explant cultures. The decidua biopsies were placed immediately into sterile cold Hank Balanced Salt Solution (HBSS; Life Technologies Inc, Burlington, Ontario, Canada) containing an antibiotic-antimycotic solution (Penicillin-Streptomycin-Amphotericin B; Life Technologies Inc) and transported to the laboratory for processing within 30 minutes of delivery.
Decidual Cell Culture
Decidual cells were prepared using modified methods as described previously. 34, 35 In brief, decidua biopsies were dissected from the uterus, cut into 1-mm 3 sections, and washed in HBSS supplemented with 100 U/mL penicillin/streptomycin and 2.5 mg/mL amphotericin B. The tissue pieces were incubated in HBSS containing 1 mg/mL collagenase XI and 1 mg/mL collagenase IA for 60 minutes at 37 C. The solution was triturated through a sterile pipette to dissociate decidual cells from the tissue pieces. Digested cells were filtered and centrifuged prior to resuspension in cell culture media supplemented with 2 mmol/L glutamine, 10% fetal bovine serum, 100 U/mL penicillin/streptomycin and 2.5 mg/mL amphotericin B. Cells were plated in 12-well culture plates and incubated at 37 C in a humidified atmosphere of 95% air/5% CO 2 . Culture medium was changed every 48 hours until the cells reached approximately 80% confluence, at which point the media was changed to serum-free media overnight prior to treatment with IL-1b (1 ng/mL) or IL-10 (5, 25, or 50 ng/mL) for 18 hours. All experiments were performed at passage 0 or passage 1 and were performed using cultured decidua from 4 women, with each experiment being performed in duplicate. Following treatments, cells were harvested for RNA and protein isolation and the culture supernatant was collected for measurement of IL-8. Cell viability was assessed at the end of selected experiments using the MTT (thiazolyl blue tetrazolium bromide) assay.
RNA Isolation, RT-PCR, and Real-Time RT-PCR
Frozen tissue samples (*30 mg) were homogenized using a Qiagen TissueLyser LT (Qiagen Inc, Toronto, Ontario, Canada). RNA was subsequently isolated using Qiagen RNeasy kits (Qiagen Inc) and 100 ng was used to synthesize complementary DNA (cDNA) with qScript cDNA SuperMix (Quanta BioSciences, Gaithersburg, Maryland). The resultant cDNA was used as a template to perform RT-PCR using gene-specific primers.
Conventional PCR was initially used to identify the presence of sPLA 2 
Immunohistochemistry
Tissue sections (5 mm) were cut onto clear glass slides (ThermoFisher Scientific, Ottawa, Ontario, Canada), dewaxed, rehydrated, and rinsed in phosphate-buffered saline (PBS). The sections were incubated in antigen unmasking solution (10 mmol/L citrate buffer, pH 6.0) for antigen retrieval and in 3% hydrogen peroxide to quench endogenous peroxidase activity. Tissue sections were treated using the ABC staining kit (Santa Cruz Biotechnology Inc) according to the manufacturer instructions. Briefly, sections were incubated for 1 hour in 
Enzyme-Linked Immunosorbent Assay
A sandwich enzyme-linked immunosorbent assay (ELISA) Kit (R&D Systems, Minneapolis, Minnesota) was used according to manufacturer instructions to quantify IL-8 released into the culture medium in response to treatment. Optical density was measured at 450 nm using a DTX880 Multimode Detector with Multimode Analysis Software (Beckman Coulter Canada Inc, Mississauga, Ontario, Canada).
Statistical Analysis
Data are presented as mean + standard error of the mean (SEM). The results were evaluated by unpaired Student t test. Statistical analysis and graphic representation was performed with GraphPad PRISM Software (GraphPad Software Inc, San Diego, California). Significance was accepted at a P value < .05.
Results
The clinical characteristics of patients are depicted in Table 1 . There were no significant differences between labor and nonlabor groups for maternal age, gravidity, parity, gestational age at delivery, or ethnicity. In the term labor group, the cervical dilation and hours of labor were significantly greater than the term nonlabor group.
Expression of sPLA 2 -IID in Human Myometrium and Gestational Tissues
Conventional RT-PCR analysis revealed expression of sPLA 2 -IID mRNA in human amnion, chorion, placenta, decidua and myometrium at term (Figure 1 ). Immunohistochemistry was used to examine the cellular localization of sPLA 2 -IID in gestational tissues at term. sPLA 2 -IID protein expression was identified in amnion (data not shown), chorion, placenta, decidua, and myometrium ( Figure 2) with unique staining patterns observed. In chorion, sPLA 2 -IID expression was observed within chorion fibroblast and trophoblast cells (Figure 2A ) and within the trophoblasts of the placenta ( Figure 2B ) and in the myometrium, the myometrial smooth muscle bundles showed staining and localization of sPLA 2 -IID protein ( Figure 2C ). Within the decidua, staining was observed in the vacuolated decidual cells and decidual stromal cells ( Figure 2D ); also shown are higher magnification images of the sPLA 2 -IID staining in the decidua (Figure 2E , Â20 and 2F Â40, respectively).
No staining was observed in controls, with no primary antibody treatment (Figure 2 insets).
sPLA 2 -IID mRNA and Protein Expression With Labor
To determine whether expression of sPLA 2 -IID mRNA or protein changed with labor, we employed real-time RT-PCR and Western blot analysis, respectively. Expression of sPLA 2 -IID was identified in the maternal gestational tissues, decidua, and myometrium ( Figure 3 ), and the fetal gestational tissues, amnion, chorion, and placenta ( Figure 4 ). In decidua, expression of sPLA 2 -IID mRNA and protein was significantly lower in term labor compared to term nonlabor samples (*P < .05), suggesting a labor-associated decrease in sPLA 2 -IID. No significant labor-associated changes were observed in myometrium ( Figure 3) , amnion, chorion, or placenta ( Figure 4 ). These results are in contrast to the labor-associated increase observed for sPLA 2 -IIA mRNA expression in myometrium, 23 suggesting that the regulatory mechanisms that govern the expression of these 2 isoforms may be unique.
Effect of Pro-and Anti-Inflammatory Mediators on sPLA 2 -IID Expression in Decidua Cells
Regulation of sPLA 2 -IID gene expression within the decidua was examined in response to treatment with the proinflammatory cytokine, IL-1b and the anti-inflammatory cytokine, IL-10. Treatment of cultured decidua cells with IL-1b (1 ng/mL) did not influence the expression of sPLA 2 -IID mRNA expression. However, treatment with IL-10 (5, 25, and 50 ng/mL) resulted in a concentration-dependent increase in sPLA 2 -IID mRNA expression as compared with nontreated cells (Figure 5A ). To determine whether the decidua cells responded to IL-1b, we tested the effect of IL-1b and IL-10 on IL-8 output from decidua cells. A significant increase in IL-8 release was observed in response to IL-1b treatment ( Figure  5B ). In contrast, IL-10 (50 ng/mL) treatment had no effect on IL-8 output and levels of IL-8 output were equivalent to nontreated controls. Cotreatment of cells with IL-1b and IL-10 had no significant effect on IL-8 release compared to IL-1b treatment alone, suggesting that IL-10 does not modulate the effects of IL-1b.
Discussion
In this study, we demonstrate that the sPLA 2 -IID isoform is expressed within the pregnant human uterus and that there is differential expression and regulation of sPLA 2 -IID within human gestational tissues. Strong evidence suggests that labor is an inflammatory process. 38 Therefore, manipulation of the classically inflammatory prostaglandin pathway has been pursued as a therapeutic target for preterm labor. Nevertheless, current treatment strategies are not always successful, suggesting that our understanding of the role of the PG pathway within the human uterus is incomplete. There are multiple genes involved at each step of the pathway, particularly the initial cleavage of membrane phospholipids by phospholipases. This led us to hypothesize that additional sPLA 2 isoforms may be expressed within human gestational tissues, contributing to the complexity of this pathway during pregnancy and labor.
In the present experiments, we demonstrate for the first time the presence of sPLA 2 -IID mRNA and protein in the maternal and fetal term gestational tissues with a distinct pattern of expression observed in the different gestational tissues. Most importantly, we show that there is a significant decrease in the expression of sPLA 2 -IID mRNA and protein in decidua with labor, while changes were not observed in amnion, chorion, placenta, or myometrium. We now show that sPLA 2 -IID mRNA expression is decreased in decidua in term laboring patients compared to term nonlaboring patients ( Figure 3 ). Previous data showed that sPLA 2 -IIA mRNA expression is increased in myometrium with the onset of labor, 23 whereas cPLA 2 -IV activity is decreased in amnion with labor onset. 24 Such tissue-specific distribution of PLA 2 isoforms may impart a mechanism to permit intricate control of PG synthesis during labor progression. Indeed, the decidua would be a desirable location for this level of control because it is located at the interface between maternal and fetal tissues. However, since we observe decreased expression of sPLA 2 -IID mRNA in the decidua, coupled with an absence of change in other gestational tissues, it is unlikely that sPLA 2 -IID contributes to the increased prostaglandin production implicated in the transition from uterine quiescence to active contractions during labor. The present observation of a downregulation of the IID isoform within decidua during labor implies reduced sPLA 2 -IID enzymatic activity, suggesting a decrease in PG production via this pathway. Since the changes in mRNA expression were closely followed by a decrease in protein expression ( Figure 3A and B), this may lead us to speculate that the fall in sPLA 2 -IID in decidua with parturition may limit AA release and prostaglandin formation from the cell membranes at the maternalfetal interface, the significance of which is not clear and warrants further investigation. We can speculate, however, that sPLA 2 -IID mRNA regulation in the decidua strongly suggests a dynamic cross-talk at the interface between maternal and fetal tissues. Such an assumption is supported by the sensitivity of sPLA 2 -IID expression to anti-inflammatory cytokine stimulation ( Figure 5 ). A switch in the expression ratio of pro-to anti-inflammatory mediators in the decidua could mediate barrier function to promote or inhibit labor onset, and the maternal immune system may be actively involved in the process of labor onset at term. 40 This role for the decidua would not be surprising, given that in the nonpregnant state, the endometrium acts as a barrier to the external environment where a strong immune component is required.
More recently, an emerging role for sPLA 2 -IID in immune function has been proposed. 17 During normal pregnancy, there is an increase in the number of regulatory T cells in the maternal periphery and decidua, which are thought to be important for maintaining immune tolerance. A fine balance between the developing fetal and the maternal immune systems is preserved during pregnancy and a disturbance in this balance may lead to miscarriage. Indeed, women who have recurrent spontaneous miscarriage have decreased levels of regulatory T cells, leading to immune imbalance and rejection of the fetus. 39 Additionally, it has recently been demonstrated that sPLA 2 -IID can act as an effector molecule of regulatory T cells, where it was shown to promote generation of additional regulatory T cells but inhibit T cell proliferation. An enzymatically inactive mutated form of sPLA 2 -IID also produced this effect, suggesting that the catalytic domain is not required to elicit this effector function, implying that sPLA 2 -IID may have anti-inflammatory and immunosuppressive properties not reliant upon its ability to cleave membrane phospholipids. 17 It is possible that sPLA 2 -IID may have a similar effect in the pregnant human uterus, where it could act to suppress the maternal immune system during pregnancy to prevent the rejection of the fetus and decreased sPLA 2 -IID expression with labor onset could permit the influx of immune cells necessary to prevent infection during labor.
In summary, we have identified the presence of sPLA 2 -IID in human gestational tissues with distinct tissue localization. We show significantly decreased expression in term laboring decidua compared to nonlaboring decidua. It is therefore probable that sPLA 2 -IID is contributing to arachidonic acid production in these tissues during pregnancy but less likely to be implicated in the increased prostaglandin synthesis associated with labor onset. However, higher levels of sPLA 2 -IID throughout pregnancy may Figure 5 . Measurement of sPLA 2 -IID messenger RNA (mRNA) expression and interleukin (IL)-8 release from decidua cells in response to IL-1b and IL-10. Decidua cells were cultured and either nonstimulated (NS) or treated with IL-1b (1 ng /mL) or IL-10 (5, 25, or 50 ng/mL) and incubated for 18 hours. A, Real-time reverse transcriptase polymerase chain reaction (RT-PCR) was used to quantify sPLA 2 -IID mRNA expression, which was normalized to the reference gene b2-microglobulin (B2M). Data represent the mean + standard error of the mean (SEM) of relative expression sPLA 2 -IID/B2M. B, IL-8 release into the cell culture supernatant assessed by enzymelinked immunosorbent assay (ELISA). Data represent the mean + SEM for n ¼ 4 patients. Statistical analysis performed by unpaired Student t test. * P < .001 compared to not significant (NS).
contribute to the production of relaxatory PGs, such as PGI 2 , implying a proquiescent role of sPLA 2 -IID in human pregnancy. In addition, regulation of sPLA 2 -IID expression at the maternalfetal interface may point to an as yet undefined role of the decidua in the maintenance of pregnancy by modulating immune function. There is a need for more specific and effective treatments for preterm labor. Our results highlight the complexity of the prostaglandin pathway in the pregnant human uterus and suggest that further research is needed to better define the roles of the PLA 2 isoforms in pregnancy and labor.
